X-376

SKU: orb1304075

Description

Ensartinib (X-376) is a potent, orally bioavailable ALK inhibitor that targets ALK fusions and mutations, disrupting oncogenic signaling and suppressing tumor growth in ALK-driven cancers. It is widely used in preclinical research, demonstrating efficacy in both in vitro cellular assays and in vivo xenograft models of non-small cell lung cancer (NSCLC).

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1365267-27-1
• MW: 547.41
• Purity: 98.72%
• Formula: C₂₅H₂₅Cl₂FN₆O₃
• SMILES: C[C@@H](Oc1cc(nnc1N)C(=O)Nc1ccc(cc1)C(=O)N1CCN(C)CC1)c1c(Cl)ccc(F)c1Cl
• Target: ALK,c-Met/HGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.65 mM);DMSO:37 mg/mL (67.59 mM)

Bioactivity

• Target IC50:
  ALK:0.61 nM|MET:0.69 nM
• In Vitro:
  Ensartinib is a selective ALK inhibitor, and provids promising advantages in terms of both Clinicalal activity and safety.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cluster of differentiation 246, CD246, cMet/HGFR, c-Met, cMet, c-Met/HGFR, ALK, ALK tyrosine kinase receptor, Anaplastic lymphoma kinase, Anaplastic lymphoma kinase (ALK), inhibit, MET, Inhibitor, HGFR, Ensartinib, X-396, X396, X-376, X376, X 376, X 396

Compound Identifiers

PubChem CID

56960447